In vitro efficacy assessment of targeted antimalarial drugs synthesized following in silico design
Year: 2017
Type: dissertation
Abstract: Malaria is a major public health problem that affects millions of lives globally. The increased \nburden of malaria requires new interventions that will address the eradication of the disease. \nCurrent interventions include vector control by using insecticide-treated bed nets and indoor \nresidual spraying, and antimalarial drugs to control the parasite. Parasite resistance has \nbeen reported for the currently used effective antimalarial drugs. To pre-empt the impact of \nparasite resistance a continued development of new antimalarial drugs that have novel \nmechanisms of action should be pursued. Antimalarial drug discovery requires that potential \nantimalarial drugs should have different drug targets to those already targeted, to lower the \nchances of resistance. Potential antimalarial drugs should preferably provide a single radical \ncure to prevent reproduction at all life cycle stages. \nThis study tested the effects of in silico designed compounds targeting plasmodial Ca2+- \ndependent protein kinases (CDPK) 1 & 4, FIKK kinases and bromodomain proteins on the \nPlasmodium parasite. These enzymes are involved in gene regulation and are important \nfactors during gene transcription. In P. falciparum the gatekeeper kinases contain small \nhydrophobic pockets near the ATP-binding site. These hydrophobic pockets allow for \nselective inhibition of these proteins at the ATP-binding site. The compounds were tested in \nvitro to determine their antiplasmodial activity. These compounds are shown to be potential \ninhibitors of the intra-erythrocytic P. falciparum parasites as three of the compounds showed \nselective cytotoxic activity at less than 1 μM against the chloroquine sensitive laboratory \nstrains (3D7 and NF54). Even though the proteins targeted by these compounds have been \npreviously indicated to play a role at specific stages during the parasite’s life cycle, the \ncompounds tested here were not able to target the sexual gametocyte stages of the \nPlasmodium parasite. Further optimisation of these compounds should be performed to \nimprove activity against both the asexual and sexual stages of the parasites.
Author: Dikeledi Matlebjane
Language: English
Topic: Malaria Research and Control
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: National Research Foundation
OpenAlex ID: W2767503185
